Patents by Inventor Gesine Kerstin Veits
Gesine Kerstin Veits has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240383886Abstract: Provided herein are compounds, compositions, and methods useful for degrading protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer 5 or a metabolic disease.Type: ApplicationFiled: December 18, 2020Publication date: November 21, 2024Inventors: Gesine Kerstin Veits, Mark E. Fitzgerald, Alexander W. Hird, James A. Henderson, Harit U. Vora, Ramzi F. Sweis, Michael E. Kort, Christopher G. Nasveschuk, Martin Duplessis
-
Patent number: 12049464Abstract: BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.Type: GrantFiled: September 1, 2022Date of Patent: July 30, 2024Assignee: C4 Therapeutics, Inc.Inventors: Christopher G. Nasveschuk, Rhamy Zeid, Ning Yin, Katrina L. Jackson, Gesine Kerstin Veits, Moses Moustakim, Jeremy L. Yap
-
Publication number: 20240245677Abstract: Selected BRD9 protein degradation compounds and morphic forms thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.Type: ApplicationFiled: March 8, 2024Publication date: July 25, 2024Applicant: C4 THERAPEUTICS, INC.Inventors: Katrina L. Jackson, Christopher G. Nasveschuk, Rhamy Zeid, Ning Yin, Gesine Kerstin Veits, Moses Moustakim, Jeremy L. Yap, Minsheng He, Robert T. Yu, Matthew J. Schnaderbeck, Kathleen Neville, Siyi Jiang, Meiqi Li, Qianwei Liu, Manjie Zheng, Jia Li, Liwei Zhang
-
Publication number: 20240199581Abstract: The present invention provides compounds or their pharmaceutically acceptable salts and their pharmaceutical compositions that can be administered to a host such as a human in need thereof for the treatment of a disorder, such as cancer, mediated by mutant BRAF. The compounds efficiently degrade Class I, II and III mutant BRAF proteins.Type: ApplicationFiled: December 8, 2023Publication date: June 20, 2024Applicant: C4 Therapeutics, Inc.Inventors: Christopher G. Nasveshuk, Katrina L. Jackson, Yanke Liang, Robert T. Yu, Martin Duplessis, Mark E. Fitzgerald, Victoria Garza, Andrew Charles Good, Morgan Welzel O'Shea, Gesine Kerstin Veits, Cosimo Dolente, David Stephen Hewings, Daniel Hunziker, Daniela Krummenacher, Piergiorgio Franceso Tommaso Pettazzoni, Juergen Wichmann
-
Patent number: 11992531Abstract: This invention provides Degronimers that have carbon-linked E3 Ubiquitin Ligase targeting moieties (Degrons), which can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.Type: GrantFiled: November 30, 2020Date of Patent: May 28, 2024Assignee: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Minsheng He, Kiel Lazarski, Gesine Kerstin Veits, Harit U. Vora
-
Publication number: 20240051953Abstract: BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.Type: ApplicationFiled: October 13, 2022Publication date: February 15, 2024Applicant: C4 Therapeutics, Inc.Inventors: Christopher G. Nasveschuk, Rhamy Zeid, Ning Yin, Katrina L. Jackson, Gesine Kerstin Veits, Moses Moustakim, Jeremy L. Yap
-
Patent number: 11753397Abstract: The invention provides cereblon binders of Formulas: or pharmaceutically acceptable salts thereof, for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway along with their use in therapeutic applications to treat medical disorders including, but not limited to cancer.Type: GrantFiled: September 24, 2020Date of Patent: September 12, 2023Assignee: C4 Therapeutics, Inc.Inventors: James A. Henderson, Gesine Kerstin Veits, Minsheng He, Christopher G. Nasveschuk, Andrew J. Phillips, Andrew Charles Good
-
Publication number: 20230233692Abstract: Novel compounds which act as protein degradation inducing moieties for proto-oncogene tyrosine-protein kinase receptor (RET), which may be either wild type RET or a mutant form of RET.Type: ApplicationFiled: February 3, 2023Publication date: July 27, 2023Applicant: C4 Therapeutics, Inc.Inventors: James A. Henderson, Christopher G. Naveschuk, Kiel Lazarski, Victoria Garza, Moses Moustakim, Jae Young Ahn, Gesine Kerstin Veits, Morgan Welzel O'Shea, Ryan E. Michael, Jeremy L. Yap, Yanke Liang, Andrew Charles Good, Mark E. Fitzgerald, Robert T. Yu
-
Patent number: 11691972Abstract: A BRD9 protein degrading compound of structure or a pharmaceutically acceptable salt thereof is provided for the treatment of a disorder mediated by BRD9, including but not limited to abnormal cellular proliferation including cancer.Type: GrantFiled: December 2, 2021Date of Patent: July 4, 2023Assignee: C4 Therapeutics, Inc.Inventors: Christopher G. Nasveschuk, Rhamy Zeid, Ning Yin, Katrina L. Jackson, Gesine Kerstin Veits, Moses Moustakim, Jeremy L. Yap
-
Publication number: 20230145336Abstract: Present invention provides compounds that cause specifically the degradation of BRAF. The present compounds are useful for the treatment of various cancers.Type: ApplicationFiled: December 19, 2022Publication date: May 11, 2023Applicant: C4 Therapeutics, Inc.Inventors: Christopher G. Nasveschuk, Martin Duplessis, Mark E. Fitzgerald, Victoria Garza, Andrew Charles Good, Katrina L. Jackson, Yanke Liang, Moses Moustakim, Morgan Welzel O'Shea, Gesine Kerstin Veits, Jeremy L. Yap, Robert T. Yu, Cosimo Dolente, David Stephen Hewings, Daniel Hunziker, Bernd Kuhn, Piergiorgio Francesco Tommaso Pettazzoni, Fabienne Ricklin, Claus Riemer, Juergen Wichmann
-
Publication number: 20230060334Abstract: BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.Type: ApplicationFiled: September 1, 2022Publication date: March 2, 2023Applicant: C4 Therapeutics, Inc.Inventors: Christopher G. Nasveschuk, Rhamy Zeid, Ning Yin, Katrina L. Jackson, Gesine Kerstin Veits, Moses Moustakim, Jeremy L. Yap
-
Publication number: 20220313826Abstract: This invention provides Degronimers that have carbon-linked E3 Ubiquitin Ligase targeting moieties (Degrons), which can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.Type: ApplicationFiled: November 30, 2020Publication date: October 6, 2022Applicant: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Minsheng He, Kiel Lazarski, Gesine Kerstin Veits, Harit U. Vora
-
Publication number: 20220098194Abstract: BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.Type: ApplicationFiled: December 2, 2021Publication date: March 31, 2022Applicant: C4 Therapeutics, Inc.Inventors: Christopher G. Nasveschuk, Rhamy Zeid, Ning Yin, Katrina L. Jackson, Gesine Kerstin Veits, Moses Moustakin, Jeremy L. Yap
-
Publication number: 20210198256Abstract: Compounds that degrade BRD9 or MTH1 via the ubiquitin proteasome pathway in a subject in need thereof for therapeutic applications are provided. The compounds provided have an E3 Ubiquitin Ligase targeting moiety (Degron) that is linked to a Targeting Ligand for BRD9 or MTH1.Type: ApplicationFiled: March 4, 2021Publication date: July 1, 2021Applicant: C4 Therapeutics, Inc.Inventors: Christopher G. Nasveschuk, Ning Yin, Katrina L. Jackson, Gesine Kerstin Veits, Moses Moustakim, Jeremy L. Yap, Rhamy Zeid
-
Publication number: 20210009559Abstract: The present invention provides cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway along with their use in therapeutic applications as described herein.Type: ApplicationFiled: September 24, 2020Publication date: January 14, 2021Applicant: C4 Therapeutics, Inc.Inventors: James A. Henderson, Gesine Kerstin Veits, Minsheng He, Christopher G. Nasveschuk, Andrew J. Phillips, Andrew Charles Good
-
Patent number: 10849982Abstract: This invention provides Degronimers that have carbon-linked E3 Ubiquitin Ligase targeting moieties (Degrons), which can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.Type: GrantFiled: November 9, 2018Date of Patent: December 1, 2020Assignee: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Chris G. Nasveschuk, James A. Henderson, Yanke Liang, Minsheng He, Kiel Lazarski, Gesine Kerstin Veits, Harit U. Vora
-
Publication number: 20190076542Abstract: This invention provides Degronimers that have carbon-linked E3 Ubiquitin Ligase targeting moieties (Degrons), which can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.Type: ApplicationFiled: November 9, 2018Publication date: March 14, 2019Applicant: C4 Theraprutics, Inc.Inventors: Andrew J. Phillips, Chris G. Nasveschuk, James A. Henderson, Yanke Liang, Minsheng He, Kiel Lazarski, Gesine Kerstin Veits, Harit U. Vora
